Cigna Investments’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $490K | Sell |
5,415
-139
| -3% | -$11.6K | 0.06% | 267 |
|
|
2026
Q1 | $445K | Sell |
5,554
-89
| -2% | -$7.34K | 0.07% | 257 |
|
|
2025
Q4 | $481K | Hold |
5,643
| – | – | 0.07% | 241 |
|
|
2025
Q3 | $439K | Hold |
5,643
| – | – | 0.06% | 266 |
|
|
2025
Q2 | $441K | Sell |
5,643
-284
| -5% | -$21.2K | 0.08% | 245 |
|
|
2025
Q1 | $429K | Sell |
5,927
-201
| -3% | -$14.4K | 0.08% | 249 |
|
|
2024
Q4 | $454K | Hold |
6,128
| – | – | 0.08% | 239 |
|
|
2024
Q3 | $405K | Sell |
6,128
-193
| -3% | -$14K | 0.07% | 275 |
|
|
2024
Q2 | $583K | Sell |
6,321
-52
| -0.8% | -$4.61K | 0.11% | 181 |
|
|
2024
Q1 | $609K | Sell |
6,373
-82
| -1% | -$6.89K | 0.11% | 179 |
|
|
2023
Q4 | $492K | Hold |
6,455
| – | – | 0.1% | 207 |
|
|
2023
Q3 | $447K | Sell |
6,455
-848
| -12% | -$68.1K | 0.1% | 202 |
|
|
2023
Q2 | $689K | Sell |
7,303
-157
| -2% | -$13.6K | 0.13% | 159 |
|
|
2023
Q1 | $617K | Sell |
7,460
-130
| -2% | -$10.2K | 0.12% | 170 |
|
|
2022
Q4 | $566K | Sell |
7,590
-48
| -0.6% | -$3.7K | 0.12% | 184 |
|
|
2022
Q3 | $631K | Sell |
7,638
-361
| -5% | -$34.7K | 0.14% | 150 |
|
|
2022
Q2 | $761K | Sell |
7,999
-2,983
| -27% | -$309K | 0.15% | 144 |
|
|
2022
Q1 | $1.29M | Sell |
10,982
-3,211
| -23% | -$360K | 0.16% | 125 |
|
|
2021
Q4 | $1.84M | Sell |
14,193
-4,928
| -26% | -$575K | 0.14% | 122 |
|
|
2021
Q3 | $2.16M | Sell |
19,121
-288
| -1% | -$32.9K | 0.16% | 118 |
|
|
2021
Q2 | $2.01M | Sell |
19,409
-3,005
| -13% | -$283K | 0.14% | 130 |
|
|
2021
Q1 | $1.88M | Buy |
22,414
+686
| +3% | +$58K | 0.13% | 144 |
|
|
2020
Q4 | $1.98M | Buy |
21,728
+1,620
| +8% | +$134K | 0.15% | 129 |
|
|
2020
Q3 | $1.6M | Sell |
20,108
-3,539
| -15% | -$276K | 0.15% | 131 |
|
|
2020
Q2 | $1.63M | Sell |
23,647
-401
| -2% | -$28.5K | 0.15% | 132 |
|
|
2020
Q1 | $1.51M | Buy |
24,048
+7,422
| +45% | +$535K | 0.19% | 116 |
|
|
2019
Q4 | $1.22M | Sell |
16,626
-1,875
| -10% | -$146K | 0.13% | 207 |
|
|
2019
Q3 | $1.47M | Buy |
18,501
+900
| +5% | +$63.2K | 0.15% | 162 |
|
|
2019
Q2 | $1.25M | Sell |
17,601
-738
| -4% | -$44.6K | 0.14% | 195 |
|
|
2019
Q1 | $1.17M | Sell |
18,339
-2,058
| -10% | -$117K | 0.13% | 200 |
|
|
2018
Q4 | $1.04M | Sell |
20,397
-252
| -1% | -$12.8K | 0.09% | 163 |
|
|
2018
Q3 | $1.02M | Buy |
20,649
+336
| +2% | +$16.4K | 0.08% | 183 |
|
|
2018
Q2 | $986K | Sell |
20,313
-3,000
| -13% | -$140K | 0.07% | 247 |
|
|
2018
Q1 | $1.08M | Sell |
23,313
-384
| -2% | -$16.7K | 0.07% | 238 |
|
|
2017
Q4 | $890K | Sell |
23,697
-726
| -3% | -$26.6K | 0.06% | 282 |
|
|
2017
Q3 | $890K | Sell |
24,423
-201
| -0.8% | -$7.67K | 0.06% | 281 |
|
|
2017
Q2 | $971K | Buy |
+24,624
| New | +$899K | 0.07% | 255 |
|
|
2017
Q1 | – | Sell |
-23,514
| Closed | -$734K | – | 757 |
|
|
2016
Q4 | $734K | Buy |
+23,514
| New | +$762K | 0.08% | 309 |
|
Other funds holding EW
Cigna Investments's EW Position: Q2 2026 in Review
Cigna Investments reduced its Edwards Lifesciences (EW) stake by 2.5% in Q2 2026, selling an estimated $11.6K and leaving 5,415 shares worth $490K. The position accounts for 0.06% of the portfolio, ranked #267.
Cigna Investments first reported a position in EW in Q4 2016 and has held it in 38 quarters since. The position peaked at $2.16M in Q3 2021. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Cigna Investments held 5,415 shares of Edwards Lifesciences worth $490K as of Q2 2026.
- Cigna Investments sold 139 Edwards Lifesciences shares in Q2 2026, an estimated $11.6K.
- Edwards Lifesciences made up 0.06% of Cigna Investments's portfolio in Q2 2026, its #267 holding.
- Cigna Investments first reported a position in Edwards Lifesciences in Q4 2016 and has held it in 38 quarters since.
- Cigna Investments's Edwards Lifesciences position peaked at $2.16M in Q3 2021.
- 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Cigna Investments's 13F filing for Q2 2026, filed 21 Jul 2026.